Clinical Trial

First in Human Study of TORL-2-307-MAB in Participants With Advanced Cancer

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated October 22, 2024 (before its estimated December 15, 2024 completion). Its status may not reflect the trial's current state.
Summary
This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of TORL-2-307-MAB in patients with advanced cancer
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2021-12-01; most recent amendment 2024-10-18.
Status change: Recruiting → Active, Not Recruiting 2024-08-06
Status change: Not Yet Recruiting → Recruiting 2022-01-24
Trial Details
NCT Number NCT05159440
Lead Sponsor TORL Biotherapeutics, LLC
Collaborators: Translational Research in Oncology
Conditions Advanced Solid Tumor, Gastric Cancer, Pancreas Cancer, Gastroesophageal Junction Adenocarcinoma
Enrollment 70 participants
Start Date 2022-01-20
Primary Completion 2024-12-15 (estimated)
Study Completion 2025-12-15 (estimated)
Updated on ClinicalTrials.gov 2024-10-22